Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Regeneron price target lowered to $1,000 from $1,100 at JPMorgan
JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...
Fierce Biotech21h
Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...
Zacks Investment Research on MSN18h
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...
Amgen (AMGN) Receives a Buy from TD Cowen
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $332.43, which is an 8.30% upside from current levels. In a report released today, DBS also maintained a Buy ...
Center for Biosimilars21h
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year
Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming ...